<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609190</url>
  </required_header>
  <id_info>
    <org_study_id>E-31/2008</org_study_id>
    <nct_id>NCT03609190</nct_id>
  </id_info>
  <brief_title>A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine</brief_title>
  <official_title>Brain Activation Patterns Under Emotional and Neurochemic Stimulation With Ketamine: A Multimodal Neuroimaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psychiatric University Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric University Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to establish a multimodal imaging approach for the investigation of
      the neural mechanisms underlying neuroreceptor regulation, glutamatergic metabolism and brain
      function that are of particular relevance for major depressive disorder (MDD) and that can be
      translated into clinical applications.

      There is growing evidence for imbalance with regard to glutamatergic neurotransmission in
      stress-related affective disorders. Further support for the hypothesis that dysfunctional
      glutamatergic signaling underlies major depressive disorder, and indeed that its reversal
      constitutes a potential efficacious mechanism of action, is provided by the evidence that
      pharmacological compounds active at the N-methyl-D-aspartate (NMDA) ionotropic glutamate
      receptor such as ketamine exert rapid antidepressant effects. As a tool compound ketamine
      enables the safe investigation of the brain region-specific effects of NMDA receptor
      antagonism in terms of glutamatergic neurotransmission, brain function and the association of
      these neural changes with emotional state, thereby allowing for increased understanding of
      the therapeutic mechanism of action.

      The possibility to simultaneously study brain perfusion (arterial spin labeling), functional
      brain activity (fMRI) and connectivity (resting state fMRI), neurometabolism (proton magnetic
      resonance spectroscopy) and metabotropic glutamate receptor densities (positron emission
      tomography) will unravel their functional interplay in the mechanisms underlying the
      regulation of mood and cognition. Combining those imaging modalities with treatment
      interventions in healthy subjects and depressed patients, this project aims at providing
      insight into the neuropharmacological effects of ketamine and its antidepressant properties.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in functional reactivity to emotional stimuli</measure>
    <time_frame>Change from baseline to 24h-post infusion</time_frame>
    <description>fMRI BOLD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glutamate concentrations in prefrontal cortex</measure>
    <time_frame>Change from baseline to 24h-post infusion</time_frame>
    <description>1H-MRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in resting-state functional connectivity</measure>
    <time_frame>Change from baseline to 24h-post infusion</time_frame>
    <description>rsfMRI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. infusion of 0.25 mg/kg S-ketamine over 40 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>i.v. infusion of NaCl over 40 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>i.v. infusion of 0.25 mg/kg S-ketamine over 40 min</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>i.v. infusion of NaCl over 40 min</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treatment resistant depressive episode

          -  no restrictions regarding antidepressant medication

        Exclusion Criteria:

          -  lifetime antidepressant treatment with ketamine

          -  lifetime recreational use of ketamine

          -  cardiovascular diseases such as hypertonia, cardiac insufficiency or myocardial
             infarct in the past six months

          -  insufficiently treated anemia

          -  hyper- or hypothyroidism

          -  lifetime increased intracranial pressure or glaucoma

          -  chronic physical diseases

          -  hepatorenal dysfunction

          -  any relevant psychiatric or neurological comorbidity, in particular dementia,
             epileptic seizures (lifetime), schizophrenia (lifetime), psychosis (lifetime), or
             post-traumatic stress disorder (current).

          -  acute suicidality

          -  substance abuse disorders

          -  recent heart or head surgery

          -  metallic body implants

          -  agoraphobia

          -  pregnancy

          -  left handedness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric University Hospital, Zurich</investigator_affiliation>
    <investigator_full_name>Milan Scheidegger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

